Advertisement

Topics

Latest "Stoke Therapeutics, Inc." News Stories - Page: 3

10:48 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Stoke Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Stoke Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Stoke Therapeutics, Inc. for you to read. Along with our medical data and news we also list Stoke Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Stoke Therapeutics, Inc. Companies for you to search.

Showing "Stoke Therapeutics" News Articles 51–75 of 7,900+

Monday 18th March 2019

Orchard Therapeutics Adds CTO Role

Zheng will oversee process development, manufacturing, quality, facilities and engineering, supply chain, and CMC program management


CARsgen to launch trial to assess CAR-T candidate in multiple myeloma

CARsgen Therapeutics announced that clearance from the Chinese National Medical Products Administration for its investigation -More- 

FDA sets new action date for Karyopharm's myeloma candidate selinexor

The FDA has extended the review period for Karyopharm Therapeutics' new drug application for selinexor for patients with pent -More- 


Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors. Mr. Legault brings to Bicycle more than 35 years of executive leadership experi...

Allergy Therapeutics surprised by the results of PQ Birch jab trial

The B301 trial was a multi-centre, double-blind, placebo-controlled study designed to test the efficacy in birch-pollen induced seasonal allergic rhinitis.

Sunday 17th March 2019

DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call

MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March 19th.  DiaMedica’s management will host a live conference call on Wednesday, March 20th at 8:00am Central Time to provide a business update and discuss the Company’s financial results. Conference C...

BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia

MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy for patients requiring hospitalization because of Community-Acquired Pneumonia (CAP). A Novel Approach to Create a New Treatment Paradigm Severe CAP is the lead indication of...

Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions

AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival in ATTR-CM patients, in all mutant and wild-type subjects. AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM, and is being evaluated in ...

Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update

Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence Dosing in Phase 1 Clinical Trial of APVO210; Dosing Scheduled to Begin March 2019 Progresses Novel 4-1BB/5T4 Bispecific Antibody A...

PDS Biotechnology Completes Merger with Edge Therapeutics

PRINCETON, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the closing of its merger with Edge Therapeutics, Inc. (“Edge”), following the approval of Edge stockholders on March 14, 2019. Following the merge...

Bone Therapeutics to present data at Herbert Fleisch / IFMRS Workshop

Press release   Gosselies, Belgium, 18 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that the Company will present a poster at the 2019 Herbert Fleisch / International Federation of Musculoskeletal Research Societies (IFMRS) Workshop “Adv...

Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019

NEW HAVEN, Conn., March 18, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the A...

Summit Therapeutics to Present at Upcoming Conferences

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at Upcoming Conferences Oxford, UK, and Cambridge, MA, US, 18 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that management will present at two upcoming conferences. Details of the conference presentations: ...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments

Product Sales of $3.9 Million for Fiscal Year 2018Initiates Financial Guidance for Full Year 2019Management to Host Conference Call at 8:00 AM ET today WAYNE, Pa., March 18, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced financial results for the fourth qua...

Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results

SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today reported its financial results for the quarter and year ended December 31, 2018, and provided a corporate update. “We are excited about the progress Arcturus...

3D bioprinter Koligo Therapeutics to list on ASX

Koligo Therapeutics (ASX:KOL), a regenerative medicine and 3D bioprinting company, will list on the Australian Securities Exchange at the end of March via an initial public offering (IPO). Koligo is dedicated to the wide distribution of pancreatic islets — the cells that make insulin to regulate blood sugar — for treating pancreatitis. It is also developing and commercialising a range of 3D b...

Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmace...

5 Top Weekly NASDAQ Biotech Stocks: Index Back in the Green

Soleno Therapeutics, Atossa Genetics, Agile Therapeutics, Syros Pharmaceuticals and Conatus Pharmaceuticals were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Index Back in the Green appeared first on Investing News Network.

Saturday 16th March 2019

Week in Review: Inventis Closes $70 Million Financing to Develop 30 Novel Therapeutics

Deals and Financings • InventisBio of Shanghai closed a $70 million Series C financing to develop its portfolio of 30 novel therapeutics for cancer and metabolic diseases;• BGI Genomics of Shenzhen formed a $50 million partnership with Natera to commercialize Natera's Signatera™ MRD (minimal residual disease) test in China; • Shanghai's Newsoara acquired Asia rights to develop...

Prexton Therapeutics gets €29m cash injection

ADC Therapeutics raises US$200m in private financing

Friday 15th March 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

NEW YORK, March 15, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investo...

Life Science Big News Roundup: Cardiol Therapeutics to Present at the 2019 LD Micro Virtual Conference; PreveCeutical Announces Preliminary Screening Results For Blue Scorpion Venom in Cell-Based Brain Cancer Model

In case you missed it, here is this week’s life science big news roundup. The post Life Science Big News Roundup: Cardiol Therapeutics to Present at the 2019 LD Micro Virtual Conference; PreveCeutical Announces Preliminary Screening Results For Blue Scorpion Venom in Cell-Based Brain Cancer Model appeared first on Investing News Network.

This Biotech Wants You to Age Well

Age is a risk factor in many diseases, such as cancer and heart disease. The German biotech Samsara Therapeutics thinks that it can make drugs that can prevent multiple conditions at once by targeting the aging process itself. Mission: To develop drugs that target the biological mechanisms underlying aging. Slowing the aging process seems like […] The post This Biotech Wants You to Age Well ...

Marker Therapeutics: Phenomenal Data In Lymphoma And Other Indications, Yet Little Recognition From The Street


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks